◆ 会议时间：2021年9月16-21日
◆ 会议地点：虚拟会议-Virtual

◆ 会议简介：

2021年欧洲肿瘤内科学会(ESMO)年会-虚拟会议将于2021年9月16-21日举行，会议由欧洲肿瘤内科学会(ESMO)主办。欧洲肿瘤内科学会年会(ESMO大会)是欧洲最负盛名和最具影响力的肿瘤学会议，每年都有超过30,000名专业人士参加会议；届时来自世界各地的临床医生、研究人员、患者倡导者、记者和制药业人士将齐聚一堂，一起分享了解肿瘤学宣的最新进展，并将科学转化为更好的癌症患者护理。ESMO 2021将成为转化研究、呈现实践变化数据和多学科讨论的卓越全球平台。ESMO 2021年大会计划将由一个300多名国际专家组成的委员会制定，内容涵盖从基础研究到癌症免疫治疗的最新发现，从肿瘤护理到姑息治疗，从罕见癌症到药物批准，等等。2020ESMO虚拟年会数字：30000余名与会者来自150多个国家/地区；230余位演讲嘉宾；2137份摘要提交。

欧洲肿瘤内科学会（ESMO）成立于1975年，是全球领先的肿瘤内科学专业组织。ESMO是肿瘤学教育和信息的参考学会，现在全球160多个国家和地区拥有超过25,000余名会员；ESMO致力于通过宣促进多学科的癌症护理，支持肿瘤学家的专业发展以及在全球倡导可持续的癌症护理，尽而为癌症患者提供最佳的护理。——未经本站许可，禁止复制转载摘录镜像本站任何内容-领域国际医学会议网。

ESMO 2021 - European Society for Medical Oncology Congress
Date: 16 - 21 September 2021
Venue: Virtual

查看大会日程>>>

ESMO 2021: An enhanced virtual experience

The ESMO Congress is the most influential oncology platform designed in Europe for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. 

In 2020, ESMO responded to the needs of an unprecedented public health environment and delivered a comprehensive virtual meeting, with an outstanding scientific and educational programme.  It demonstrated ESMO’s full commitment to the immediate global dissemination of new data in oncology and to advancing the education of oncology professionals even under the most challenging circumstances.

The ESMO Congress 2021 will again present the very latest advances in the treatment of cancer and offer an excellent educational programme, with opportunities for an exchange of ideas among delegates from all around the world.

A virtual format with an enhanced virtual experience, focusing on offering more interactivity across the breadth of its programme. There will be more opportunities to engage with key opinion leaders, possibilities to contribute to customising the content of certain sessions, chances to debate with investigators, and much more.

摘要提交截止日期-Abstract Submission Deadlines

* A preliminary abstract indicating the data expected to be available by the LBA deadline must be submitted online by 5 May 2021 as an “intent to submit a late-breaking abstract”.

点此提交摘要>>>Submit Abstract>>>

提交摘要规则>>>ESMO Congress 2021 Abstract Submission Regulations>>>

Outcome notifications-结果通知

Outcome notifications are expected to be made available to first authors by 20 July 2021.

Submission categories-提交类别

• Basic science
• Biliary tract cancer, incl. cholangiocarcinoma
• Biomarkers (agnostic)
• Breast cancer, early stage
• Breast cancer, locally advanced
• Breast cancer, metastatic
• CNS tumours
• Colorectal cancer
• Developmental therapeutics
• Endocrine tumours
• General interest
• Genitourinary tumours, prostate
• Genitourinary tumours, non-prostate
• Gynaecological cancers
• Haematological malignancies
• Head and neck cancer, excluding thyroid
• Hepatocellular carcinoma (HCC)
• Investigational immunotherapy
• Melanoma and other skin tumours
• Neuroendocrine tumours
• New diagnostic tools
• NSCLC, early stage
• NSCLC, locally advanced
• NSCLC, metastatic
• Oesophagogastric cancer
• Palliative care
• Pancreatic cancer
• Psycho-oncology
• Public policy
• Sarcoma
• SARS-CoV-2 and cancer
• SCLC
• Supportive care
• Thoracic malignancies, other
• Thyroid cancer
• Translational research (agnostic)
• Tumour biology and pathology
• Cancer nursing: Digital innovations in health
• Cancer nursing: Palliative and end-of-life care
• Cancer nursing: Patient and occupational safety
• Cancer nursing: Health promotion, prevention and screening
• Cancer nursing: Supportive care and symptom management
• Cancer nursing: Roles and leadership
• Cancer nursing: SARS-CoV-2 and cancer
• Cancer nursing: Ethics in cancer care

Late-breaking abstracts (LBA)-最新数据摘要

Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 5 May 2021 will be considered for late-breaking status. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to the ESMO 2021, and a pre-planned analysis must be scheduled between the regular submission deadline of 5 May 2021 and the late-breaking submission deadline of 17 August 2021.

The final late-breaking abstract deadline of 17 August 2021 is under no circumstances to be considered as an extension of the general submission deadline.

A preliminary abstract indicating the data expected to be available by the late-breaking abstract deadline must be submitted online by 5 May 2021 as an “intent to submit a late-breaking abstract”. The preliminary abstract must include the title, first author with full contact details and Declaration of Interest, background, methods, expected results and expected conclusions.

The ESMO 2021 Scientific Committee will review the “intent to submit late-breaking abstract” and will determine if the study can be identified as potential late-breaking abstract.

First authors receiving a positive outcome of this review will be required to submit online the entire abstract, including final author string, results and conclusions plus any table (if applicable) by the late-breaking abstract deadline (17 August 2021).

Trial in progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO 2021.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections: Background and Trial design.

• Recruitment must have already begun or have been completed by the abstract submission deadline of 5 May 2021.
• Abstracts including results or preliminary data will be rejected.
• Trial in Progress abstracts can be accepted for Poster presentation only.
• Encore TiP abstracts will not be accepted. 

Presentation and publication of accepted abstracts

The ESMO 2021 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Presidential Symposium – Oral presentations by authors presenting cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.
• Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
• Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.

Publication schedule for accepted abstracts

The publication schedule for accepted abstracts will be released in due course.

ESMO2021 注册费：

ESMO Members and non-members - ESMO会员与非会员注册费

EONS Members

*Applicable to ESMO members from developing countries only. At the time of application, developing countries are defined by ESMO according to the World Bank classification of low, lower-middle and upper-middle countries based
** ESMO members must be under 40 and in training to qualify for this fee
*** Applicable to individuals who belong to patient advocacy groups and are Members of ESMO.

The ESMO Congress 2021 offers: 

• Streaming of live presentations with interactive chat/Q&A 
• Scientific sessions on demand 
• Industry satellite symposia on demand  
• ePosters 
• Virtual exhibition  
• Post-event resources 

Webcasts

The congress webcasts will include all the sessions of the official programme, where speaker permission is granted.

2020年虚拟年会议数字播报：